Aborehab N.M.Osama N.Department of BiochemistryFaculty of PharmacyOctober University for Modern Sciences and Arts (MSA University)Giza12611Egypt; Department of BiochemistryFaculty of PharmacyMenoufia UniversityMenoufia32511Egypt2020-01-092020-01-09201914752867https://doi.org/10.1186/s12935-019-0868-0PubMed ID :https://t.ly/OX3BAScopusBackground: Cervical cancer is the fourth most common cancer affecting women worldwide. Paclitaxel/Carboplatin is one of the most commonly prescribed regimens in cervical cancer treatment. Although chemotherapeutic drugs are very effective, severe side effects and development of drug resistance limits the use of these drugs. The use of natural products with anticancer activity may help to partially overcome these issues. Methods: In the present study, we investigated the ability of Gallic acid, to potentiate the anti-cancer effects of Paclitaxel, Carboplatin and Paclitaxel/Carboplatin combination in human HeLa cells by performing MTT assay, cell cycle analysis and RT-PCR assay and Western blotting for some apoptotic markers. Results: Our results revealed that the highest cytotoxic effect, the highest induction of apoptosis and significant elevation in P53 and Caspase 3 levels was seen in Paclitaxel/Gallic acid combination. Conclusion: These results indicate that Gallic acid potentiates Paclitaxel effect and that Paclitaxel/Gallic acid combination could represent a promising alternative with lower side effects-for Paclitaxel/Carboplatin combination in treatment of cervical cancer treatment. � 2019 The Author(s).EnglishCaspase 3Gallic acidHeLa cellsP53Paclitaxelcarboplatincaspase 3gallic acidpaclitaxelprotein p53antineoplastic activityapoptosisArticlecell cycle progressioncell viabilitycontrolled studycytotoxicitydrug effectdrug efficacydrug mechanismdrug potentiationdrug responsefemaleHeLa cell linehumanhuman cellIC50MTT assayreal time polymerase chain reactionWestern blottingArticlehttps://doi.org/10.1186/s12935-019-0868-0PubMed ID :